Clinical trial
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
NCT02837757 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Everolimus Modulation of Anti-tumor T CD4 Immune Responses
- Lead sponsor
- Centre Hospitalier Universitaire de Besancon
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- November 30, 2015
- Completion date
- December 18, 2019
- Enrollment
- 14 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic renal cancer